论文部分内容阅读
目的探讨急性心肌梗死经皮冠状动脉介入术(PCI术)中应用比伐芦定的疗效。方法 356例行PCI术的急性心肌梗死患者,随机分为研究组与对照组,各178例。研究组术中应用比伐芦定抗凝治疗,对照组应用肝素抗凝治疗。比较两组临床疗效。结果研究组发病30 d内不良事件的发生率为5.62%,显著低于对照组的11.80%,差异有统计学意义(P<0.05)。两组治疗期间药物相关不良反应的发生率对比,差异无统计学意义(P>0.05)。结论急性心肌梗死PCI术中应用比伐芦定具有显著的抗凝效果,且安全性佳,适于临床应用。
Objective To investigate the effect of bivalirudin in patients with acute myocardial infarction who underwent percutaneous coronary intervention (PCI). Methods A total of 356 patients with acute myocardial infarction undergoing PCI were randomly divided into study group and control group, with 178 cases in each group. The study group was treated with bivalirudin anticoagulation and the control group with heparin anticoagulation. The clinical efficacy of the two groups were compared. Results The incidence of adverse events in study group within 30 days was 5.62%, which was significantly lower than that in control group (11.80%, P <0.05). There was no significant difference in the incidence of drug-related adverse reactions between the two groups (P> 0.05). Conclusion The application of bivalirudin in patients with acute myocardial infarction has significant anticoagulant effect and is safe and suitable for clinical application.